KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Shares Outstanding (Diluted Average) (2016 - 2025)

Regeneron Pharmaceuticals has reported Shares Outstanding (Diluted Average) over the past 16 years, most recently at $108.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $108.6 million for Q4 2025, down 5.65% from a year ago — trailing twelve months through Dec 2025 was $108.6 million (down 5.65% YoY), and the annual figure for FY2025 was $108.6 million, down 5.65%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $108.6 million at Regeneron Pharmaceuticals, up from $107.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for REGN hit a ceiling of $116.2 million in Q3 2024 and a floor of $107.2 million in Q3 2025.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $113.4 million (2022), compared with a mean of $112.6 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 2.62% in 2022 and later fell 7.75% in 2025.
  • Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $112.2 million in 2021, then rose by 1.16% to $113.5 million in 2022, then grew by 0.18% to $113.7 million in 2023, then increased by 1.23% to $115.1 million in 2024, then fell by 5.65% to $108.6 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $108.6 million (Q4 2025), $107.2 million (Q3 2025), and $109.9 million (Q2 2025) per Business Quant data.